1 / 34

Rift Valley Fever

Rift Valley Fever. Sherine Shawky, MD, Dr.PH Assistant Professor Department of Community Medicine & Primary Health Care College of Medicine King Abdulaziz University shshawky@hotmail.com. Rift Valley Fever. Acute febrile viral disease Affecting animals & humans

oshin
Download Presentation

Rift Valley Fever

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rift Valley Fever Sherine Shawky, MD, Dr.PH Assistant Professor Department of Community Medicine & Primary Health Care College of Medicine King Abdulaziz University shshawky@hotmail.com

  2. Rift Valley Fever • Acute febrile viral disease • Affecting animals & humans • Causes influenza-like illness • May lead to high morbidity, mortality & economic loss

  3. Geographic Location & Geologic Feature of Rift Valley • Length: 6,000miles • Site: Lebanon to Mozambique • Largest part: Kenya • Development: Subterranean forces • Feature: Dambos

  4. Causes of Outbreaks Rainfall or Inundation Wetlands & Stagnant water Vegetation Growth Flourishing of mosquitoes Transmission of Infection

  5. Outbreaks in the Last Half Century

  6. RVF Virus Glyco- protein spikes Lipid envelope L S G1 M G2 transcriptase Coiled nucleocapsid RNA+N protein

  7. Mode of Transmission • Mosquitoes • Other blood suckling insects • Contact with blood or other body fluids of infected animals • Consumption of infected milk

  8. Mode of Transmission(cont.) • Contact with blood or other body fluids of infected humans in late stages of disease • Airborne transmission • Inoculation through broken skin

  9. Target • Liver: focal necrosis • RBCs: haemagglutination • Brain: necrotic encephalitis

  10. Clinical Picture 1- Non-Human Host • Fever • Hepatitis • Abortion • Death • Adults: 10-30% • Neonates: 100%

  11. 2- Human Host • Incubation period of 2-6 days • Asymptomatic • Flu-like illness • Abdominal pain • Photophobia • Recovery in 2-7days

  12. Rate: 0.5-2.0% Onset: 1-3 weeks Presentation Localized pain Blurred vision Loss of vision: 1.0-10.0% Lesions: Macular lesions Retinitis Retinal detachment Death: rare Complications of RVF 1- Ocular Lesions

  13. Rate: < 1.0% Onset: 1-3 weeks Death: rare Presentation: Severe headache Vertigo Seizures Coma 2- Meningoencephalitis

  14. Rate: < 1.0% Onset: 2-4 days Presentation: hemorrhagic phenomenon Lesions: Acute fulminant hepatitis DIC Hemolytic anemia CFR: 50.0% 3- Haemorrhagic fever

  15. High Risk Groups • People who sleep outdoors at night • Slaughterhouse workers, butchers veterinarians and others who handle blood, other body fluids or tissues of infected animals

  16. High Risk Groups (cont.) • Doctors and nurses in contact with infected cases at late stages of the disease • Laboratory technicians • Travellers visiting epidemic areas

  17. Diagnosis of RVF • Antibody detection • ELISA • EIA • Virus detection • Virus isolation • Antigen detection • PCR

  18. Prevention & ControlI. Animal • Vaccination of unaffected animals • Live attenuated vaccine • Killed vaccine • Notification of affected animals • Application of safe insecticides to eradicate blood suckling insects

  19. I- Animal(cont.) • Periodic surveillance of susceptible animals to assess immune status • Application of quarantine measures for testing of imported animals • Rapid burial of dead bodies

  20. II- Vector • Removal of stagnant water • Weekly treatment of water collections using insecticides • Application of insecticides every other day in all gardens • Removal of objects that can act as possible water containers

  21. III- Humans: 1- General Measures • Sleeping indoors • Using bed nets during sleep • Putting screens on windows • Wearing clothes that protects whole body

  22. III- Humans: 1-General Measures (cont.) • Applying mosquito repellents • Using spray on clothes • Avoiding peaks of mosquito activity • Avoiding presence near vegetations in the evening

  23. III- Humans1-General Measures (cont.) • Avoiding direct contact with animals • Washing hands after contact with animals, their blood or other body fluids • Avoid drinking raw milk

  24. III- Humans2- Community Measures • Health education • Epidemiologic research program • Active disease surveillance • Check measures at air, sea and land entry points

  25. III- Humans3- Occupational Measures • Wearing masks, gloves, gowns and other barriers according to infected host’s condition • Laboratory samples should be handled by trained staff

  26. III- Humans3- Occupational Measures (cont.) • Application of water, soap and antiseptic solution on exposed parts • Application of copious water and eye wash solution on exposed conjunctiva

  27. Management of Suspected Cases • Notification • Ascertainment of cases • Identification, screening and surveillance of contacts

  28. CBC Urea Creatinine AST, ALT ALP,Bilirubin Albumin PT & PTT LDH & CPK Hepatitis A IgM & IgG, HBsAg, HBcAB, HCV Ab RFV seriology & viral culture Recommended Investigations For Suspected Cases

  29. Management of unhospitalised Patients • Isolation at home • Contacts should wear masks, gloves and protective clothes • Safe disposal of patients linens & clothes • Close follow-up for 6 weeks

  30. Shock Decreased urine output AST & ALT > 200U/mL Bilirubin>100 mol/L Thrombocytopenia< 100,000/mm3 Anaemia< 8gm/dL Creatinine>150mol/L Confusion or other CNS manifestation Evidence of DIC Indications For Hospitalisation

  31. Management of Hospitalised Patients • General Supportive Measures • Isolation in negative airway pressure room • Safe disposal of soiled linens • Safe disposal of solid medical waste • Safe sewage disposal

  32. Management of Hospitalised Patients (cont.) • Ribavirin, Interferon, Immune Modulators & Convalescent Phase Plasma give promising results • Introduction to ICU or haemodialysis unit if indicated

  33. Hospital discharge after: • Improvement in general status • Decline in liver symptoms • Recovery from DIC • Follow-up in ophthalmology and medical clinics for 6 weeks • Safe burial practice for dead cases

  34. Conclusion • RVF is spreading outside Africa • Although often mild, may lead to high morbidity and mortality • No vaccine for humans • No specific treatment • Preventive measures are crucial

More Related